https://doi.org/10.55788/db8616ec
“TAVI has become the preferred treatment option for most patients with symptomatic severe aortic valve stenosis. Current evidence for young, low-risk patients, however, remains restricted to device-specific and industry-sponsored trials and that’s potentially limiting the applicability to routine practice,” Prof. Moritz Seiffert (BG University Hospital Bergmannsheil, Germany) explained the motivation for the DEDICATE-DZHK6 study (NCT03112980) [1].
This investigator-initiated, multicentre, randomised-controlled trial strove to reflect routine medical care by allowing the use of any kind of contemporary devices per design. It compared TAVI with SAVR in 1,414 participants aged 65–85 years with low-to-intermediate surgical risk. Over 55% of the participants were men and the mean age was about 74 years. The STS-PROM score, a surgical risk calculator, was 1.8% and 1.9% in the 2 study groups, indicating a low-risk cohort.
Prof. Seiffert presented the results of the primary safety endpoint of all-cause death or stroke at 1 year. The primary efficacy endpoint will be evaluated at year 5 of the study. The present analysis tested for non-inferiority of TAVI versus SAVR with a rejectable absolute between-group difference of 1%.
The results of the co-primary endpoint of all-cause death or stroke at 12 months revealed a cumulative incidence rate of 5.4% in the TAVI group compared with 10% in the SAVR group, corresponding to a 47% lower outcome probability (HR 0.53; 95% CI 0.35–0.79) and a P<0.001 for non-inferiority of TAVI (see Figure). Results for TAVI versus SAVR were consistent for the individual components of the primary endpoint including an HR of 0.43 (95% CI 0.24–0.73) for death and HR 0.61 (95% CI 0.35–1.06) for stroke, respectively.
Figure: DEDICATE-DZHK6 primary safety endpoint: all-cause death or stroke a 1 year [1]
CI, confidence interval; HR, hazard ratio; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.
“In the DEDICATE trial, an investigator-initiated, independent trial designed to evaluate patients that mirror our daily clinical routine with aortic stenosis at low or intermediate surgical risk, TAVI with a prosthesis selection based on operator-discretion was non-inferior to SAVR with respect to death from any cause or stroke at 1 year,” concluded Prof. Seiffert.
- Seiffert M, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement in patients at low to intermediate risk- one-year outcomes of the randomised DEDICATE-DZHK6 trial. LB5, Session 412, ACC 2024 Scientific Session, 6–8 April, Atlanta, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Interatrial shunt for HF: neutral primary endpoint but potential benefit in HFrEF Next Article
Self-expanding versus balloon-expendable TAVR in patients with small aortic annuli »
« Interatrial shunt for HF: neutral primary endpoint but potential benefit in HFrEF Next Article
Self-expanding versus balloon-expendable TAVR in patients with small aortic annuli »
Table of Contents: ACC 2024
Featured articles
Matters of the heart: late-breaking news from the American College of Cardiology
Heart Failure and Cardiomyopathy
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
IMPROVE-HCM: Promising results for ninerafaxstat in non-obstructive HCM
Acute Coronary Syndrome and Acute Myocardial Infarction
ACS: Necessary DAPT after PCI may be shorter than currently advised
AEGIS-II: ApoA-1 did not reduce MACE in patients with myocardial infarction but may provide benefit in patients with high LDL levels
REDUCE-AMI: Re-evaluating the role of routine beta-blockade in patients with acute myocardial infarction
Interventional Cardiology in 2024
Self-expanding versus balloon-expendable TAVR in patients with small aortic annuli
Safety of TAVI non-inferior to SAVR for patients with lower surgical risk
Interatrial shunt for HF: neutral primary endpoint but potential benefit in HFrEF
Peripheral artery disease: procedure-guidance by IVUS superior to angiography
IVUS-guided PCI beats angiography in patients with acute coronary syndrome
Addressing frailty in patients undergoing TAVR
Novel Developments in Risk Factor Management
Preventive PCI of vulnerable intracoronary plaque leads to favourable outcomes
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
BRIDGE-TIMI 73a: Olezarsen halves triglyceride levels
Plozasiran: A novel approach to severe hypertriglyceridaemia
High-risk and very high-risk patients meet LDL-cholesterol targets with lerodalcibep
No cardioprotective effect of ACE inhibitors in patients with cancer
Best of Posters
SGLT2 inhibition in heart failure more advantageous for women than men
Anxiety and depression: Lifestyle influential in MACE prevention
Meet the Trialists
Related Articles
September 4, 2024
RESHAPE-HF2: Not a “tie-breaker” about TEER in heart failure
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com